中文摘要：

在全身給藥后，影響納米粒在體內(nèi)命運(yùn)的因素仍是一個(gè)備受關(guān)注的研究領(lǐng)域。其中尤為引人關(guān)注的問題是，用癌癥特異性抗體配體進(jìn)行標(biāo)記（即“主動(dòng)靶向"）是否優(yōu)于其未標(biāo)記的對(duì)應(yīng)物（即“被動(dòng)靶向"）。利用三種免疫變異小鼠模型的乳腺癌，我們證明，抗體標(biāo)記納米粒的瘤內(nèi)滯留是由腫瘤相關(guān)樹突狀細(xì)胞、中性粒細(xì)胞、單核細(xì)胞和巨噬細(xì)胞決定的，而非由抗體-抗原相互作用決定。全身暴露于任何一種納米粒都會(huì)誘導(dǎo)免疫反應(yīng)，導(dǎo)致CD8+ T細(xì)胞浸潤(rùn)和腫瘤生長(zhǎng)延遲，且這種效應(yīng)與抗體的治療活性無關(guān)。這些結(jié)果表明，無需治療性載荷，全身暴露于納米粒即可誘導(dǎo)抗腫瘤免疫反應(yīng)。我們的結(jié)論是，宿主的免疫狀態(tài)和實(shí)體瘤的微環(huán)境是癌癥納米醫(yī)學(xué)研究中的關(guān)鍵變量，并且納米技術(shù)可能具有應(yīng)用于癌癥免疫治療的潛力。

英文摘要：

The factors that influence nanoparticle fate in vivo following systemic delivery remain an area of intense interest. Of particular interest is whether labeling with a cancer-specific antibody ligand (“active targeting") is superior to its unlabeled counterpart (“passive targeting"). Using models of breast cancer in three immune variants of mice, we demonstrate that intratumor retention of antibody-labeled nanoparticles was determined by tumor-associated dendritic cells, neutrophils, monocytes, and macrophages and not by antibody-antigen interactions. Systemic exposure to either nanoparticle type induced an immune response leading to CD8+ T cell infiltration and tumor growth delay that was independent of antibody therapeutic activity. These results suggest that antitumor immune responses can be induced by systemic exposure to nanoparticles without requiring a therapeutic payload. We conclude that immune status of the host and microenvironment of solid tumors are critical variables for studies in cancer nanomedicine and that nanoparticle technology may harbor potential for cancer immunotherapy.

論文信息：

論文題目：Enhancing the regenerative effectiveness of growth factors by local inhibition of interleukin-1 receptor signaling

期刊名稱：Science Advances

時(shí)間期卷：Vol 6, Issue13(2020)

在線時(shí)間：2020年3月25日

DOI: 10.1126/sciadv.aay1601

產(chǎn)品信息：

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes&Control Liposomes

辦事處：靶點(diǎn)科技

Clodronate Liposomes氯膦酸鹽脂質(zhì)體清除小鼠乳腺癌模型里巨噬細(xì)胞。荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes見刊于Science Advances：在乳腺癌模型中，納米顆粒與免疫細(xì)胞的相互作用主導(dǎo)了腫瘤滯留，并誘導(dǎo)了T細(xì)胞介導(dǎo)的腫瘤抑制。

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體清除巨噬細(xì)胞的材料和方法：

In vivo macrophage depletion

Athymic nude mice growing HCC1954 tumors (n = 3 with two tumors each) were treated with two consecutive doses of clodronate liposome (CL) (Liposoma, Netherlands) via intraperitoneal (300 μl per animal) injection. After the second dose of CL, BH nanoparticles were injected (5 mg of Fe per mouse intravenously) and euthanized 24 hours later to harvest tumors for ICP-MS.

巨噬細(xì)胞清除材料和方法文獻(xiàn)截圖：在乳腺癌模型中，納米顆粒與免疫細(xì)胞的相互作用主導(dǎo)了腫瘤滯留，并誘導(dǎo)了T細(xì)胞介導(dǎo)的腫瘤抑制。